ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Clinical application of modified Yihuang Decoction for the treatment of cervical high-risk HPV persistent infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPersistent high-risk HPV (HR-HPV) infection is a major cause of cervical cancer. While vaccines exist, treatment options for those already infected are limited. This study aims to evaluate the effectiveness and immune response of combining human interferon α2b (hIFN) with modified Yihuang Decoction (YHD) for HR-HPV infection.
methodsThis trial was conducted with 108 patients diagnosed with persistent HR-HPV infection. Participants received either hIFN monotherapy or a combination of hIFN and YHD (hIFN-YHD) for 3 months, followed by a 6-month follow-up. The primary outcomes included clinical efficacy, HR-HPV clearance rates, and changes in immune markers, such as IFN-γ, IL-4, and FPR3, in cervical biopsy tissues and vaginal lavage fluid.
resultsTreatment with hIFN-YHD resulted in significantly higher recovery (46.8%) and overall response rates (85.1%) compared with hIFN monotherapy (28.9% and 60.0%, respectively; p < 0.05). The negative conversion rate for HR-HPV was also significantly higher in the hIFN-YHD group, especially in patients with single and multiple infections (p < 0.001). Immunological analysis revealed increased FPR3 and IFN-γ expression and reduced IL-4 levels in the hIFN-YHD group. Additionally, hIFN-YHD treatment significantly increased IFN-γ levels and decreased IL-4 levels in vaginal lavage fluid (p < 0.001).
conclusionThe combination of hIFN and YHD significantly improves clinical outcomes and enhances immune responses in patients with persistent HR-HPV infection.
Indexed as
Identifiers
42584811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.